1Folkman J. Tumor angiogenesis: therapeutic implications. N Eng J Med, 1971, 285(21): 1182-1186.
2Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003, 9(6): 669-676.
3Avastin (bevacizumab) package insert. South San Francisco, CA: Genentech Inc; July 2009.
4Sandier A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-ceU lung cancer. N Eng J Med, 2006, 355(24): 2542-2550.
5Reck M, Pawel JV, Zatloukal P, et al. Phase Ⅲ trial ofcisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol, 2009, 27(8): 1227-1234.
6Dansin E, Tsai CM, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SaiL study (MO19390). Eur J Cancer Suppl, 2009, 7(2): 556.
7Wu YL, Zhou CC, Jiang GL, et al. First-line bevacizumab plus chemotherapy in Chinese pateints with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): results of the SaiL trial (MO19390). APCC 2009 [ abstr: P95].
8Zhu XL, Wu SH, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis, 2007, 49(2): 186-193.
9Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphrylation. Nature, 1999, 399(6736): 601-605.
10He H, Venema VJ, Gu XL, et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/ KDR activation of c-Src.J Bio Chem, 1999, 274(35): 25130-25135.
